Related Experiment Video
Updated: Dec 20, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Olig2 SUMOylation protects against genotoxic damage response by antagonizing p53 gene targeting
Huiqing Liu1, Weiji Weng1, Rongjun Guo1,2
1Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Abstract:
Posttranslational modifications of nuclear proteins, including transcription factors, nuclear receptors, and their coregulators, have attracted much attention in cancer research. Although phosphorylation of oligodendrocyte transcription factor 2 (Olig2) may contribute to the notorious resistance of gliomas to radiation and genotoxic drugs, the precise mechanisms remain elusive. We show here that in addition to phosphorylation, Olig2 is also conjugated by small ubiquitin-like modifier-1 (SUMO1) at three lysine residues K27, K76, and K112. SUMOylation is required for Olig2 to suppress p53-mediated cell cycle arrest and apoptosis induced by genotoxic damage, and to enhance resistance to temozolomide (TMZ) in glioma. Both SUMOylation and triple serine motif (TSM) phosphorylation of Olig2 are required for the antiapoptotic function. Olig2 SUMOylation enhances its genetic targeting ability, which in turn occludes p53 recruitment to Cdkn1a promoter for DNA-damage responses. Our work uncovers a SUMOylation-dependent regulatory mechanism of Olig2 in regulating cancer survival.
Insights
Small ubiquitin-like modifier-1 (SUMO1) conjugation of oligodendrocyte transcription factor 2 (Olig2) is crucial for glioma resistance to genotoxic drugs. SUMOylation and phosphorylation of Olig2 suppress apoptosis and enhance cancer survival.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Posttranslational modifications (PTMs) of nuclear proteins are critical in cancer.
- Oligodendrocyte transcription factor 2 (Olig2) phosphorylation is implicated in glioma drug resistance, but mechanisms are unclear.
Purpose of the Study:
- To investigate the role of Olig2 SUMOylation in glioma resistance to genotoxic agents.
- To elucidate the interplay between Olig2 SUMOylation and phosphorylation in regulating cancer cell survival.
Main Methods:
- Western blotting to detect Olig2 SUMOylation and phosphorylation.
- Cell-based assays to assess Olig2's role in cell cycle arrest and apoptosis.
- Chromatin immunoprecipitation to evaluate p53 binding to the Cdkn1a promoter.
Main Results:
- Olig2 is SUMOylated at lysine residues K27, K76, and K112.
- SUMOylation, along with TSM phosphorylation, is essential for Olig2's antiapoptotic function.
- Olig2 SUMOylation suppresses p53-mediated cell cycle arrest and apoptosis, conferring resistance to temozolomide (TMZ).
- SUMOylated Olig2 inhibits p53 recruitment to the Cdkn1a promoter, impairing DNA damage response.
Conclusions:
- Olig2 SUMOylation is a novel regulatory mechanism controlling glioma cell survival.
- Targeting Olig2 SUMOylation may offer a therapeutic strategy for overcoming chemoresistance in gliomas.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...

